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1ABSTRACT:
Organ donation is regulated zealously, but when it comes to tissue donation, there is little oversight. Lack of
proper oversight and mandated guidelines in the human tissue industry is problematic as human tissue can
transmit disease. In the early 1990s, several disasters motivated the FDA to provide for an overall regulatory
regime in an industry it once declined to regulate at all. However, it is estimated that industry revenue will
rise to $1 billion annually by 2003; up from $20 million a decade ago. This industry explosion, fueled by
biomedical innovation and the entry of for-prot companies, has put added pressure on the FDA to advance
more thorough regulatory standards to protect human health and safety. In response, the FDA has advanced
a proposed regulatory approach that would address a broader scope of products, include more comprehensive
requirements to prevent the transmission of communicable disease, and apply tiered requirements based on
the characteristics of such products. However, until the proposed rules are nalized, tissue banks have no
external requirements for quality and handling of tissue if they are not accredited by private organizations or
licensed by New York or Florida. Furthermore, the human tissue industry is an unfunded mandate and the
FDA lacks adequate resources to enforce published standards and regulations. To date, the FDA has chosen
not to impose user fees on the industry, though the possibility remains. In the meantime, organ procurement
organizations look on with more than benign interest at the developments within the tissue banking industry.
Their worry is that negative public image directed at the human tissue industry will be shared unfairly by
their industry as the general public does not dierentiate between tissue donation and organ donation.
TEXT:
2I. INTRODUCTION
On November 9, 2001, 23-year old Brian Lykins died after receiving donor knee tissue contaminated with
clostridia sordelli, a close relative of the bacteria that cause gas gangrene.1 In July 2000, Florida-based
tissue bank, Regeneration Technologies, announced plans to combine bone and tissue products from multiple
donors, despite fears that the process spreads disease.2 In 2001, federal investigators reported some human
tissue banks repeatedly retest tissue until it complies with safety regulations, a process that is scientically
unsound and unsafe.3
To the uninitiated, the above examples represent what must be stark violations of safety standards imposed
by the Food and Drug Administration (FDA), the powerful federal agency whose mission is to: \[P]romote
and protect the public health by helping safe and eective products reach the market in a timely way, and
monitoring products for continued safety after they are in use."4 However, quite to the contrary, the tissue
banks involved in the above examples have committed no violation of pertinent FDA regulatory standards
in eect at the time.
Donations of organs like hearts and livers are regulated zealously, but when it comes to human tissues
{ ligaments, tendons, bones, skin and other body parts { there is little oversight.5 As if to emphasize the
yawning regulatory hole, an increasing number of for-prot companies have begun to compete with non-prot
organizations in the collection and processing of donor tissue. This combination of insucient regulatory
oversight and a booming private industry, worries a growing number of experts, who note that improperly
1See Sandra Blakeslee, Lack of Oversight In Tissue Donation Raising Concerns, N.Y. Times, Jan. 20, 2002, at Section 1
Page 1.
2See generally Mark Katches, Mixing bones from several bodies dees tissue banks' regulations, The Orange Country
Register, Jul. 9, 2000.
3See John A. MacDonald, Human Tissue Banks' Safety Questioned, Federal Monitoring Called `A Shot in the Dark', The
Hartford Courant, May 25, 2001, at A2.
4See FDA (visited March 6, 2002)<http://www.fda.gov/opacom/hpview.html>.
5See Blakeslee, supra note 1.
3handled tissue can transmit dangerous, even lethal infections.
The purpose of this paper is to examine the present state of the human tissue industry and the FDA's eorts
to regulate the burgeoning industry. The paper begins with a background discussion about the human
tissue industry and the tremendous growth being experienced by the industry. The paper then highlights
the major historical developments of FDA's regulatory regime, then briey examines alternative regulatory
bodies, such as professional societies and the States. Finally, the paper will look at the challenges faced by
the FDA as it seeks to provide eective oversight in an area that is currently an unfunded mandate.
II. BACKGROUND
A. What Is Tissue Donation?
Tissue donation includes anything from the human body that is not a vital organ.6 This includes blood
vessels, bone, bone marrow, connective tissues, corneas, heart valves, middle ears, and skin.7 Body parts
that fall under the broad area of tissue donations can be harvested, sterilized, processed and cut into more
than a hundred dierent pieces, then oered fresh, frozen or freeze-dried for use in more than 400 dierent
surgical procedures.8 Accident victims in need of reconstructive surgery would be one example of the kind
of surgical procedure that rely on donated tissue.
In 1999, the number of tissue donors reached 20,000, up from 6,000 in 1994.9 One organ and/or tissue donor
can help more than 50 people.10
6Tissue Banks: Industry Needs Greater FDA Regulation, American Health Line, Jan. 8, 2001.
7See U.S. Department of Health and Human Services, Organ & Tissue Donation (visited March 12, 2002) <
http://www.organdonor.gov/TissueDonorBrochureNewCard.pdf>.
8Pam Adams, Organ Donations Raise Ethical Issues, Copley News Service, Dec. 18, 2000.
9See American Health Line, supra note 6.
10See Adams, supra note 8.
4B. Compare with Organ Donation
Given the industry's involvement in the harvesting of human body parts, the public often incorrectly analo-
gizes tissue donation to organ donation. However, organ and tissue donation are dierent, both in the way
they are regulated and in their clinical application.
Organ donation is strictly regulated and organ procurement organizations (OPOs) closely align their opera-
tions in support of the public interest. The process itself is life-saving. Unfortunately, donor organs are not
readily available. Over 80,000 Americans are waiting for life-saving organ transplants.11 Tissue donation
on the other hand is life-enhancing. The tissue banks that are largely responsible for the industry are not
as closely aligned to the public interest, and the for-prot tissue banks operate with an eye to maximizing
returns. In addition, there is no comparable shortage of tissue for donation, or urgency for tissue trans-
plants.12
Despite the dierences between the two industries, to protect the future of both the industries, it is impera-
tive that the tissue banking industry is held to the same high standards as the organ procurement industry.
This is because negative public perception of the tissue banking industry can jeopardize organ donation. For
example, at a hospital in Florida, the reported activities of a local tissue bank caused a family to decline
their option of organ donation.13
C. Tissue Donation and Disease
Lack of proper oversight and mandated guidelines for tissue donation procedures has proven problematic as
11See American Medical Association (March 15, 2002)<http://www.ama-assn.org/ama/pub/category/1945.html>.
12Prepared Testimony of William Minogue, M.D. Chairman, Board of Direcors, Washington Regional Transplant Consor-
tium, Federal News Service, May 24, 2001.
13Id.
5human tissue can transmit disease. Over the years, the FDA has published a series of rules and guidelines
to better protect public health and safety in this burgeoning eld. In essence, FDA oversight has attempted
to ensure that human tissue pieces conform to strict federal safety standards to prevent the spread of
communicable diseases such as HIV and hepatitis.
II. INDUSTRY GROWTH
A. The Growth
The National Organ Transplant Act makes it illegal to buy and sell organs and tissue.14 It does, however,
allow tissue agencies to charge reasonable fees for collecting, shipping, processing, marketing and implanting
them.15 This loophole has helped to fuel a fast-growing industry in which body parts are more likely referred
to in terms of products and prots than as charitable "gifts."16
Gifts of cadaveric tissue from generous families to private and not-for-prot tissue banks have evolved into a
multimillion dollar industry where one tissue donor can easily yield about $80,000 worth of tissue "products,"
not including organs, for a commercial business.17 One body can yield more than 130 pieces of tissue once
it is extracted, sterilized, cut up, packaged and sold.18 The processing fee for a cornea is $1,600 in Illinois.
A heart valve can go for as high as $4,000. A piece of cartilage for knee surgery can range from $1,000 to
$4,000 and an Achilles tendon can run from about $900 to $2,000, depending on the supplier.19
A decade ago tissue industry revenue totaled $20 million, but by 2003 it is estimated that revenue will rise
14Mike Dorning, Body Parts Trade Faces U.S. Probe, Chicago Tribune, Jun. 9, 2000, at N1.
15See Blakeslee, supra note 1.
16See Adams, supra note 8.
17Id.
18See Stephen J. Hedges and William Gaines, Donor Bodies Milled Into Growing Prots, May 21, 2000, at C1.
19See Adams, supra note 8.
6to $1 billion annually.20 Revenues of the nation's 10 largest non-prot tissue banks and organ banks dealing
in tissue totaled $230 million in 1998, the last year for which gures are publicly available. Two years prior
to that, those same organizations reported revenues of $183 million.21
The engine driving this market growth is biomedical innovation.22 Tissue is being put to new uses, and
processing has grown more sophisticated. Entrepreneurial rms have stepped in to develop and market new
products and treatments from human tissue.23 A handful of companies have patented techniques for turning
tissues into extremely useful products, like bones that are tooled into special shapes or ground into powders
and pastes.24
B. Entry of For-Prot Tissue Banks
An increasing number of for-prot companies are now competing with non-prots for this processing business.
This sti competition can result in use of medically questionable tissue by rms that have a nancial interest
in producing as much material as they can.25 As stated by Dr. William Minogue, board chairman for the
Washington Regional Transplant Consortium, "These organizations often operate from prot motives that
supersede the public interest."26 Indeed, for-prot entities need access to human tissue in order to generate
revenue and are under shareholders' pressure to increase their market position to maximize prots. These
companies are not required to take the overall donation interests of the public into account and, unlike
20Ellen Beck, FDA Told To Do More Tissue Bank Inspections, United Press International, May 24, 2001.
21See Hedges and Gaines, supra note 18.
22See Blakeslee, supra note 1.
23Prepared Testimony of George F. Grob Deputy Inspecor General for Evaluation and Inspections U.S. Department Of
Health and Human Services Before the Senate Committee on Governmental Aairs Permanent Subcommitee on Invesigations,
Federal News Service, May 24, 2001.
24See Blakeslee, supra note 1.
25See Laura Meckler, Congress Examines Tissue Bank Operators, Dayton Daily News, May 25, 2001.
26Id.
7OPOs, their boards have no requirements to represent the public interest. 27
C. Standards of Practice
Unfortunately, standards of practice have not kept pace with market growth and development.28 As a result,
for-prot corporations inuencing tissue donation with questionable practices can hinder the overall organ
and tissue donation process, and bring about serious negative consequences.
Local tissue and organ banks compete and even pay for access to hospitals, morgues and hospices where
they can nd families willing to donate a deceased loved one's remains.29 In several states, funeral homes
have gone into partnership with tissue banks.30 If a family agrees to donate tissue, technicians trained by
the tissue bank remove tissue at the funeral home. The level of training varies, but critics of the practice say
many such technicians cannot identify problems like undiagnosed tuberculosis or cancer in donor bodies.31
The altruism of donation is further clouded by the complicated relationships that have developed between
the non-prot and for-prot companies in the tissue business.32 Though donor families give a relative's tissue
to a non-prot tissue bank, some of those groups turn around and sell the tissue to for-prot companies.
It is not unusual for the non-prot and the for-prot to have supply agreements, processing contracts and
formal partnerships.33
27See Minogue, supra note 12.
28See Grob, supra note 23.
29See Hedges and Gaines, supra note 18.
30Unregulated Tissue Donations Concern Federal and State Ocials, Death Care Business Advisor, Feb. 21, 2002.
31Id.
32See Hedges and Gaines, supra note 18.
33Id.
8III. FDA REGULATION
As the industry continues to advance, problems stemming from a lack of regulatory oversight grows more
acute. Over the last decate, the FDA has responded to the increasing pressure and advanced regulatory
standards in an industry where it once declined to regulate at all. Currently, the FDA regulates the tissue
industry through the Center of Biologics Evaluation and Research (CBER). However, it has taken the FDA
many years to decide upon the appropriate regulatory paradigm. Only until very recently, has the FDA
developed comprehensive protection of the public through guidance to the tissue industry.
A. Early Regulatory Decisions
Prior to 1993, the FDA regulated most cellular and tissue-based products on a case-by-case basis.34 When
regulation of a certain tissue-based product was deemed necessary, the FDA did so under existing regulatory
schemes. This ad-hoc approach led to fragmented and sometimes inconsistent results. For example, the FDA
regulated some products as medical devices { such as dura mater and heart valves { and subjected them to
all applicable medical device provisions, including pre-market notication.35 However early tissue banking
operations involving products such as eye and bone tissue were not regulated.36 The FDA had no general
policy as to which tissue products would be subject to any particular regulatory requirement.
34See Martha A. Wells, Overview of FDA Regulation of Human Cellular and Tissue-Based Products, 52 Food & Drug L. J.
401 (1997).
35See Isabel P. Dunst & Robert P. Brady, Human Cellular and Tissue Products: Regulation, Coverage, and Reimbursement,
J. Biolaw & Bus., Winter 1999, at 6.
36D. Michael Strong, Tissue Banks: Drafting New Rules for Grafting, Bus. & Soc'y Rev., Sept. 22, 1991.
9B. 1993 Interim Rule
In the early 1990s, two events spurred FDA into action. First, AIDs-tainted body parts distributed by
LifeNet, a reputable Virginia organ recovery agency, killed 3 people in 1991.37 Around the same time, FDA
receive reports of tainted foreign tissue being imported into the United States without adequate testing and
screening.38
In response to these serious problems, on December 14, 1993, the FDA promulgated its Interim Rule on
Human Tissue Intended for Transplanation.39 The Agency did so under Section 361(a) of the Public Health
Service (PHS) Act of 1944, which authorizes \regulations...necessary to prevent the introduction, transmis-
sion or spread of communicable diseases..." In accordance with that authority, the FDA required all tissue
banks perform serological tests to screen for viruses such as hepatitis and HIV.40 The importation of tissue
from abroad also became prohibited unless it has been shown to meet all FDA requirements.41 The regu-
lations also outlined criteria for tissue donor selection, and authorized the FDA to inspect any facility that
recovers, processes or distributes tissue for transplant. A tissue bank that refuses to allow FDA inspection
may be prosecuted under Section 368 of the PHS Act.42
The rules were eective immediately and included \conventional" banked tissue, such as skin, bone, and eye.
Excluded from the rule was vascularized organs, human milk, reproductive tissue, and bone marrow. Also
excluded were products regulated as drugs, biological or medical devices.43
37See Bill Sizemore, Body Parts: Big Business Medical Advances and a Growing Willingness to Donate Organs Have
Bolstered the Largely Unregulated Trade of Human Parts, The Virginian-Pilot, Apr. 29, 2001.
38Christopher Joyce, FDA Will Regulate Importation of Human Tissue, NPR { Weekend Edition, Dec. 11, 1993.
3958 Fed. Reg. 65513
40See Antonio Pereira, M.D., Overview of FDA Regulation of Bone as a Tissue, PPT Slide Presentation, Aug. 2, 2000; also
see FDA (visited March 17, 2002)<http://www.fda.gov/cber/summaries/pereira080200.htm>.
41See Joyce, supra note 38.
42Prepared Statement of Bob Rigney Chief Executive Ocer of The American Association of Tissue Banks (AATB) Before
the Senate Committee on Governmenal Aairs, The Permanent Subcommittee of Investigations, Federal News Service, May
24, 2001.
43See Pereira, supra note 40.
10C. 1997 Final Rule
On July 29, 1997, the FDA issued its nal regulations (21 CFR 1270) that were broader in scope than its
interim rule. The nal regulations cover all facilities that are engaged in the recovery, screening, testing,
processing, storage or distribution of human tissues. It required that specied minimum required medical
screening and infectious disease testing be performed. Records documenting such screening and testing for
each human tissue must be available for inspection by the FDA. For human tissue that is imported, the
importer must notify the director of the FDA district that has jurisdiction over the port of entry through
which the tissue is imported or oered for import. All imported tissue must be quarantined until the FDA
releases it.44
The 1997 nal rule also requires tissue banks to permit inspection by authorized FDA inspectors of its facil-
ities, equipment, processes, products and all records necessary to determine compliance with the regulation.
These inspections can be made without notice; the frequency of the inspections is left to the agency's discre-
tion. Upon nding that human tissue may be in violation of the FDA's regulations, the agency may serve
the tissue bank with an order for recall and/or destruction, or it may take possession of and/or destroy the
tissue in question.45
FDA has not extended its regulation to Organ Procurement Organizations (OPOs), nor has it covered hos-
pitals or other clinical facilities that only receive and store human tissue for transplantation within the
same facility. However, hospitals or clinics that participate in recovery, screening, testing, processing, or
distribution of human tissue in addition to storage for transplantation are covered by the rule.46
The Final Rule was made eective on July 29, 1997.




The scope of FDA's current regulation (21 CFR Part 1270) is limited to donor screening and testing to
prevent transmission of HIV and Hepatitis.47 However the FDA recognizes that, stricter standards for tissue
donor suitability should be imposed. Unlike organ transplants which are life-saving, tissue transplants are,
for the most part, life-enhancing. Therefore, if tissue donor evaluation and recovery practices are unsafe, a
recipient can be subjected to unnecessary risk.
To address identied regulatory deciencies, the FDA is in the process of revising 21 CFR Part 1270.
The proposed regulatory approach would address a broader scope of products, include more comprehensive
requirements to prevent the transmission of communicable disease, and would apply tiered requirements
based on the characteristics of such products. Three proposed regulations currently comprise the new
regulatory regime being considered:
a. Registration Proposed/Final Rule
In 1998, the FDA published the proposed rule \Establishment Registration and Listing for Manufacturers of
Human Cellular and Tissue-Based Products." The proposed rule required cell and tissue establishments to
register with the FDA and submit a list of their human cellular and tissue-based products. Final rules for
this measure was issued on January 19, 2001 and made eective April 4, 2001 for establishments previously
regulated { bone, skin, corneas, tendon; reproductive establishments have until January 2003 to register. In
compliance with the new regulation, at least 387 tissue banks have registered with the FDA as of August
2001.48 This number is far in excess of the 154 tissue banks identied by the Oce of Inspector General
47See Grob, supra note 23.
48See Martha A. Wells, Update on the Implementation of FDA's Establishment Registration and Product Listing Regulation,
Slide Presentation, Aug. 28, 2001; or see <http://www.fda.gov/cber/summaries/wellsaatb.htm>.
12in a report published in early January 2001.49 Part of the reason lies in the fact that some tissue banks
have multiple sites registered. Additionally, many banks that are not required to register { for example, if
they supply tissue only for research { have nonetheless registered. Finally, there are at least 71 eye banks
included in the count and eye banks were not covered by the Inspector General's report.50
b. Donor Suitability Proposed Rule
Proposed rule for \Suitability Determination for Donors of Human Cellular and Tissue-Based Products" was
issued on September 30, 1999. The proposed regulation would require tissue banks to test for communicable
disease: HIV 1/2, Hepatitis B/C, Treponema Pallidum, HTLV I/II, CMV, Chlamydia Trachomatis, and
Neisseria Gonorrhea. Also required will be donor screening for risk factors and clinical evidence of disease
for: HIV, Hepatitis B/C, CJD, Chlamydia trachomatis , and Neisseria gonorrhea.
c. Current Good Tissue Practices (CGTP) Proposed Rule
Issued on January 8, 2001, the proposed new rule for \Current Good Tissue Practice for Manufacturers of
Human Cellular and Tissue-Based Products" outlines the following key elements:
1)
Establishment of a quality program, which would evaluate all aspects of the rm's
operations, to ensure compliance with GTP;
2) Maintenance of an adequate organizational structure and sucient personnel;
3) Establishment of standard operating procedures for all signicant steps in manufacturing;
4) Maintenance of facilities, equipment and the environment;
49See OIG, Oversight of Tissue Banking, Jan. 200; located at <http://www.fda.gov/cber/tissue/ovrst0101.pdf>.
50See Wells, supra note 48.
135) Control and validation of manufacturing processes;
6) Provisions for adequate and appropriate storage;
7) Record keeping and management;
8) Maintenance of a complaint le;
9) Procedures for tracking the product from donor to recipient, and from recipient to donor.51
Not included in the FDA's 3-tiered requirements are organs, bone marrow, xenografts, blood, and se-
creted/extracted products.52
IV. OTHER REGULATORY BODIES
A. Private Accreditation
a. American Association of Tissue Banks
The American Association of Tissue Banks (AATB) is a scientic, not-for-prot, peer group organization
founded in 1976 to facilitate the provision of transplantable cells and tissues of uniform high quality in quan-
tities sucient to meet national needs.53 The Association is not aliated with, supported by, or chartered
by the Government. At the core of its mission is public health { the AATB is dedicated to ensuring that
human tissues intended for transplantation are safe and free of infectious disease, of uniform high quality,
51FDA Proposes New Rules for \Good Tissue Practice", FDA Talk Paper, Jan. 5, 2001; also see
<http://www.fda.gov/bbs/topics/ANSWERS/ANS01062.html>.
52See Jesse L. Goodman, FDA and Tissues in the Year 2000, PPT Slide Presentation, Oct. 3, 2000; also see FDA (visited
March 17, 2002)<http://www.fda.gov/cber/summaries/goodman92000.htm>.
53See AATB (vistied March 13, 2002)<http://www.aatb.org>.
14and available in quantities sucient to meet national needs.54
To ensure that tissue banking activities are performed in a professional manner, the AATB initiated a pro-
gram of Inspection and Accreditation of tissue banks in 1986.55 Accreditation addresses not only donor
screening and testing practices, but operational and organizational aspects, such as qualications of tissue
bank personnel and banks' safety practices, equipment testing, facilities, labeling, and quality assurance
programs.56 To comply with antitrust laws, the AATB does not dierentiate between for- prot and not-
for-prot tissue banks. Indeed, the current list of AATB accredited tissue banks includes both for-prot and
not-for- prot entities. 57
Seeking accreditation is purely voluntary and currently only 58 tissue banks are accredited.58 The remaining
banks are under no obligation to meet the standards or policies set by the association, and for many banks
there is no incentive to seek accreditation.59
Despite the relatively low participant ratio, the safety record established by the AATB's accredited members
demonstrate great promise. During the past seven years, tissue banks accredited by the AATB have dis-
tributed more than four million allografts to surgeons without a single reported case of disease transmission
from donor to recipient. 60
b. Eye Bank Association of America
The Eye Bank Association of America (EBAA) is a not-for-prot organization of eye banks dedicated to
the restoration of sight through the promotion and advancement of eye banking.61 Established in 1961 by
the American Academy of Ophthalmology's Committee on Eye Banks, the EBAA is the oldest national
54See Rigney, supra note 42.
55See AATB (visited March 13, 2002)<http://www.aatb.org/aatbaccr.htm>.
56See Grob, supra note 23.
57See Rigney, supra note 42.
58See Grob, supra note 23.
59Id.
60See Rigney, supra note 42.
61See EBAA (visited March 16, 2002)<http://www.restoresight.org>.
15association of transplantation organizations in the United States.62 The EBAA developed medical stan-
dards in 1980 and since then, has continuously reviewed and revised those standards to reect medical and
technological advancements.
The EBAA currently represents 92 U.S. eye bank organizations (or 99 percent of the entire domestic eye
banking community), and provides 97 percent of all corneal tissue for transplantation.63 All eye banks are
non-prot 501(c)(3) organizations whose mission is to procure and provide donated human eye tissue for
sight restoring transplantation procedures.
Like the AATB, the EBAA routinely inspects its member organizations to ensure compliance with the
association's prescribed standards.
B. States
New York and Florida are the only two States that operate oversight programs requiring that tissue banks
be licensed and inspected. A few states, including California, Georgia and Maryland, require that banks be
licensed, either as tissue banks or as laboratories.64
a. New York
New York's Tissue Resource Program was established in 1990.65 Pre-dating FDA's 1993 interim rules, the
New York program is the rst comprehensive oversight program for tissue banks in the country and maintains
62See EBAA (visited March 16, 2002)<http://www.restoresight.org/general/about ebaa.htm>.
63See EBAA (visited March 16, 2002)<http://www.restoresight.org/newsroom/newsroom.htm>.
64Oce of Inspector General, Oversight of Tissue Banking, January 2001 at 5.
65Following enactment of the State's Public Health Law Article 43-B.
16the most rigous standards by far. Under New York regulations,66 all tissue banks seeking licensure within
the state are required to establish a very rigid organizational structure, tissue tracking and mandatory blood
testing of tissue donors.67
In addition to meeting FDA requirements to screen and test for HIV and hepatitis, New York requires banks
to test for HTLV and syphilis. New York also requires tissue banks to meet specic standards for each type
of tissue { musculoskeletal, cardiovascular, and skin { that the bank procures, processes, or stores. These
standards relate to donor qualications, tissue retrieval processes, laboratory testing, and disposal of unused
tissue.68
Licensure requires an initial application and on-site survey. Tissue banks do not pay a fee for licensure, but
they must provide an annual report of statistics on procurement, processing and distribution.69
b. Florida
Licensing of tissue banks in Florida State is conducted by Florida's Agency for Health Care Administration.
To obtain a license from the State, tissue banks must submit a $1,000 non-refundable application fee. There
is also an annual fee of 0.25% of gross Florida revenues, with a minimum of $1,000 and a maximum of
$35,000.70 Applicants must disclose the bank's ownership, as well as information on equipment and donor
selection and testing criteria. Florida requires tissue banks to comply with current FDA regulations.
66Part 52 of Title 10 of New York Codes, Rules and Regulations
67See IIAM General Information (visited March 14, 2002)<http://www.iiam.org/geninfo/backgrnd.htm>.




A. Regular Inspection and Enforcement
For nearly 8 years after the FDA's initial regulation of tissue in 1993, the tissue bank industry enjoyed a clean
safety record in that no new cases of disease transmission through human tissue were identied. However, the
death of Brian Lykins in November 2001 reinforced the point that despite signicant regulatory advancements
in the current system, the need for continued vigilance and monitoring remain.
In a 2001 study published by the Oce of Inspector General71, several problems with current FDA oversight
was identied:
1)
Some tissue banks have never been inspected by the FDA;
2) FDA lacks a prescribed cycle for reinspection of tissue banks;
3) The number and location of tissue banks are unknown;
4)
current scope of FDA's regulations are limited.72
Even prior to Brian Lykin's infection by clostridium sordelli, FDA inspectors uncovered serious deciencies
in tissue banks' screening and testing practices.73 A natural assumption would be that similar problems
71OIG report did not address eye or reproductive tissue.
73See Grob, supra note 23.
18exist at tissue banks not yet inspected by FDA inspectors. However, at the time of the Inspector General's
study, only 118 tissue banks had ever been inspected by the FDA, and of that number, 68 were inspected
only once.74 Due to limited resources, the agency has established a priority list for follow-up inspections,
focusing on banks with the most serious deciencies.75
Since the Inspector General's oce issued their report, the FDA has begun inspecting all known tissue
banks.76 The initiative was facilitated when the FDA's Registration Rule became eective on April 4, 2001.
Prior to requiring registration, the FDA had no eective method of locating, much less inspecting, all the
tissue banks in operation.
B. Resource Restraints
Despite the acknowledged need to conduct adequate inspections of registered tissue banks, the FDA does
not have enough money to regularly inspect all tissue banks.77 FDA has indicated that because regulation
of tissue banks is an unfunded mandate, it has had to borrow resources from other programs to carry out
these inspections.78
FDA ocials budgeted $4.35 million on inspections for 2001, but acknowledged the agency does not have
enough money to inspect U.S. tissue banks as often as the agency would like.79 The agency's goal for scal
year 2001 was to inspect those tissue banks identied by the Oce of Inspector General as never inspected
and any other banks the new registration requirements bring to its attention.80 According to Kathryn C.
Zoon, the FDA's director of research, the ideal would be an inspection every two years. But due to lack of
74Oce of Inspector General, Oversight of Tissue Banking 7-8, January 2001 at 7-8.
75See Grob, supra note 23.
76Id.
77See Laura Meckler, Congress Examines Tissue Bank Operators, Dayton Daily News, May 25, 2001.
78See Grob, supra note 23.
79See MacDonald, supra note 3.
80See Beck, supra note 20.
19funding, the agency focuses on banks where problems were found in the past.81
Re-inspections are conducted by the FDA based on levels of risk.82 Tissue banks cited for violations and
ordered to take corrective action are at the top of the re-inspection list, followed by tissue banks where
voluntary corrective action was requested. 83
a. User Fees
To address budgetary shortages, the FDA has, in the past, attempted to introduce user fees to support the
agency's cost of oversight. However, this measure was met with great resistance from the AATB, EBAA,
and other non-prot organizations within the industry. Speaking before the Subcommittee on Regulation,
Business Opportunities, and Technology on Capitol Hill, the National Head of Tissue Services of the Amer-
ican Red Cross, Randolph May, reiterated his organization's strong resistance to the idea of user fees. He
noted that user fees were only introduced by the FDA after extensive negotiations with the for-prot phar-
maceutical industry who were losing millions from the growing backlog of new drug applications awaiting
review by the FDA.84 When user fees were nally approved, it was not without signicant benet to the
pharmaceutical industry: \There was a clear quid pro quo, in that in exchange for the user fees, the FDA
would agree to hire 600 new inspectors and expedite the processing of new drug applications."85 By con-
trast, Mr. May notes that the U.S. tissue banking industry is mostly comprised of tissue banks that are
small, not-for-prot, community-based operations. These tissue banks depend on the public perception that
donating the tissue of a deceased loved one is a humanitarian service, not a commercial activity. The fear is
that the imposition of user fees for tissue banking would jeopardize this perception.86
81See MacDonald, supra note 3.
82See Beck, supra note 20.
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84Testimony October 15, 1993 S. Randolph May, Ph.D. National Head Tissue Services American Red Cross House Small
Business Subcommittee: Regulation of Human Tissue Banks, Federal Document Clearing House Congressional Testi-
mony, Oct. 15, 1993.
85Id.
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20Mr. Randoph May's arguments have been repeated by many others in the industry and the FDA has ac-
knowledged these important points. However, the agency notes that its resources are limited and they must
balance the benets to be gained by allocating resource to tissue regulation against using those resourcs to
address other risks. Indeed, enacting a statute without the necessary resources to establish the program and
sustain it over time will not accomplish much. The FDA argues that user fees should be strongly considered
as a funding mechanism and bear the majority of the cost. It points out that standard setting and other
functions of a federal oversight program would provide real value to the tissue banking community in terms
of public credibility and a level playing eld, and it is fair to ask that community to bear the cost.87
b. Possible Solutions
To date, the FDA has chosen not to impose user fees on the industry; though the possibility remains. The
entry of for-prot companies into the tissue banking business has undercut at least part of the argument
that the industry is lled with small not-for-prot organizations and the industry cannot sustain the cost of
user fees. One must merely look to the $173.3 million in revenue brought in by the four leading for-prot
tissue companies in 1999.88 As previously mentioned, in 1998, the revenue of the 10 largest not-for-prot
organizations was $230 million. Not only does the entry of for-prot organizations place increasing stress on
the FDA's resources, but the amount of revenue they generate does more to undercut the public image that
tissue donation is a humanitarian service and not a commercial activity than any user fees. On the other
hand, there should be some nicentive for tissue banks and for-prot enterprises to invest in the development
of new and useful innovations in technology. In addition, the FDA recognizes the concern that user-fee costs
would likely be passed on to consumers.89
Perhaps the answer lies in a combination of user fees and greater collaboration with the States and private
87Testimony October 15, 1993 Kathryn Zoon PhD Director of Center for Biologics Evaluation & Research FDA House
Small Business Subcommittee: Regulation of Human Tissue Banks, Federal Document Clearing House Congressional
Testimony, Oct. 15, 1993.
88See Hedges and Gaines, supra note 18.
89See Zoon, supra note 81.
21organizations such as the AATB and the EBAA. Experienced private entities, including professional societies
and voluntary standard-setting or accrediting organizations, can provide valuable service to the agency, often
at a lesser cost than it would take for the agency itself to carry out similar tasks.
VII. CONCLUSION
The need for greater regulatory oversight in the tissue banking industry has never been greater. Tissue
donation has become a near billion-dollar-a year national industry and the entry of for-prot companies
underscore the need for federal oversight to protect public health and safety. However, until FDA's CGTP
and Donor Suitability proposed rule is nalized, tissue banks have no external requirements for quality and
handling of tissue if they are not accredited by AATB, the EBAA, or licensed by New York or Florida. As
such, it is imperative that the FDA work quickly to nalize their proposed rules.
In the meantime, organ procurement organizations look on with more than benign interest at the develop-
ments within the tissue banking industry. Their worry is that negative public image directed at the human
tissue industry will be shared unfairly by their industry as the general public does not dierentiate between
tissue donation and organ donation.
At the crux of the problem of insucient regulatory oversight, is the limited resources the FDA has at its
disposal. Given the non-prot nature of much of the industry, and its reliance on donations of cadaveric
tissue from generous families, user fees do not seem entirely appropriate. However, the FDA still has other
avenues, such as professional societies and the States, that it can leverage to help ensure industry compliance
with its newly proposed regulations.
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